,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2013-10-11 02:58:00,"We recently reinstated our Neutral recommendation on Boston Scientific Corporation ( BSX ), a leading medical devices company.",0.5371678471565247,0.056454695761203766,0.4063774645328522,positive,0.4807131588459015
1,2013-10-11 02:58:00,"After several quarters of weak performance, we are encouraged with the company's efforts at revival, as reflected in its improved second-quarter 2013 results.",0.9453255534172058,0.019890669733285904,0.03478384017944336,positive,0.9254348874092102
2,2013-10-11 02:58:00,"While challenges still remain in the core stent and defibrillators businesses, we are optimistic about the recent update on the company's growth objective that conveys significant new additions .",0.8737459182739258,0.01450780127197504,0.11174631118774414,positive,0.8592380881309509
3,2013-10-11 02:58:00,The stock currently carries a Zacks Rank #2 (Buy).,0.2876644730567932,0.010478651151061058,0.7018568515777588,neutral,0.2771858274936676
4,2013-10-11 02:58:00,"Boston Scientific reported a strong second quarter with adjusted EPS of $0.18, beating the year-ago adjusted EPS of $0.17 as well as the Zacks Consensus Estimate of $0.16.",0.9550567269325256,0.024581538513302803,0.020361686125397682,positive,0.9304751753807068
5,2013-10-11 02:58:00,"Revenues were up 2% at CER to $1.809 billion, ahead of the Zacks Consensus Estimate of $1.779 billion.",0.9553295969963074,0.024455787613987923,0.020214589312672615,positive,0.9308738112449646
6,2013-10-11 02:58:00,The top- and the bottom-line results also exceeded the company's guided range.,0.9364806413650513,0.02568201906979084,0.037837304174900055,positive,0.9107986092567444
7,2013-10-11 02:58:00,Margin expansion is another upside.,0.6896650791168213,0.01863533817231655,0.2916996479034424,positive,0.6710297465324402
8,2013-10-11 02:58:00,"Based on these encouraging numbers, BSX raised its 2013 revenue and EPS guidance.",0.9353277087211609,0.01739099621772766,0.04728133603930473,positive,0.9179366827011108
9,2013-10-11 02:58:00,"Although Boston Scientific's result remains challenged by headwinds in its core segments, we are encouraged by the company's various measures to combat this challenging economic scenario.",0.8871132731437683,0.016600126400589943,0.09628662467002869,positive,0.8705131411552429
10,2013-10-11 02:58:00,"Recently, Boston Scientific came up with significant new additions and alterations in its growth objectives.",0.7036905884742737,0.011752085760235786,0.28455737233161926,positive,0.6919385194778442
11,2013-10-11 02:58:00,"According to the company, the earlier growth objectives, provided in 2010 and considered ""too aggressive"", required alterations since the challenging economic scenario led to a notable change in the end market.",0.25655850768089294,0.19263549149036407,0.5508059859275818,neutral,0.06392301619052887
12,2013-10-11 02:58:00,"Accordingly, Boston Scientific mentioned that the Interventional Cardiology (IC) and Cardiac Rhythm Management (CRM) markets might stabilize over the next 3 years, leading to a slight improvement in sales (low single-digit growth).",0.9520624279975891,0.020390216261148453,0.027547262609004974,positive,0.931672215461731
13,2013-10-11 02:58:00,Management also provided an update on its view for the medium term (2014-2015) and the long term (2016-2017).,0.02943458966910839,0.006329708732664585,0.9642357230186462,neutral,0.02310488000512123
14,2013-10-11 02:58:00,We believe that a fresh take on growth objectives by new management after a period of pressurized core business will lead to a turnaround.,0.9424269199371338,0.01482949499040842,0.04274367541074753,positive,0.9275974035263062
15,2013-10-11 02:58:00,"However, as of now, we prefer to remain on the sidelines until further visibility is obtained in this regard.",0.04556071758270264,0.007796884514391422,0.9466423988342285,neutral,0.03776383399963379
16,2013-10-11 02:58:00,"Other Stocks to Consider

Some of the other medical devices stocks worth a look are INSYS Therapeutics ( INSY ), Hill-Rom Holdings, Inc. ( HRC ) and diaDexus, Inc. ( DDXS ).",0.038079358637332916,0.008975385688245296,0.9529452323913574,neutral,0.029103972017765045
17,2013-10-11 02:58:00,All these stocks carry a Zacks Rank #2 (Buy).,0.1801605224609375,0.0149730509147048,0.8048664331436157,neutral,0.16518747806549072
18,2013-10-11 02:58:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
19,2013-10-11 02:58:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
